Traws Pharma (TRAW) investor relations material

Executive summary

• Advanced Tivoxavir marboxil (TXM) as a next-generation antiviral for influenza prevention, with preparations for a Phase 2a human challenge trial in the UK and a new tablet formulation showing extended coverage in preclinical studies.

• Secured up to $60 million in private PIPE financing, including $10 million upfront and milestone-based warrants, to fund clinical development and key milestones into Q1 2027.

• Submitted IND to FDA for US development of TXM, currently on clinical hold due to toxicology data concerns, with plans to resolve the hold and advance US trials by late 2026.

• Ratutrelvir Phase 2a topline data showed a differentiated safety and efficacy profile versus PAXLOVID® in COVID-19 patients, with faster symptom resolution in PAXLOVID®-ineligible patients.

• Leadership changes included the appointment of a new CEO, CFO, and an independent board director with expertise in finance and strategy.

Financial highlights

• Revenue for 2025 was $2.8 million, up from $226,000 in 2024, mainly due to deferred revenue from a terminated oncology licensing agreement.

• Net income for 2025 was $9.2 million ($0.83 per basic share), compared to a net loss of $166.5 million ($35.21 per share) in 2024.

• R&D expenses were $12.1 million, slightly down from $12.8 million in 2024, reflecting lower oncology program costs.

• G&A expenses decreased to $8.5 million from $12.3 million, primarily due to reduced professional and consulting fees.

• Cash and cash equivalents were $3.8 million at year-end 2025, down from $21.3 million at year-end 2024, excluding proceeds from the April 2026 PIPE financing.

Outlook and guidance

• Current cash, including PIPE proceeds and warrants, expected to fund operations and completion of the TXM challenge trial into Q1 2027.

• Aiming to advance TXM through a UK challenge study in summer 2025 and resolve FDA clinical hold for US trials by late 2026.

• Will adjust dosing regimen (monthly, biweekly, or weekly) based on challenge study results and market research.

• Final analysis of ratutrelvir Phase 2a data will inform next clinical and regulatory steps.